ABSTRACT
PURPOSE: To investigate whether Sp1 can ameliorate sepsis-induced myocardial injury and explore the potential molecular mechanism. METHODS: The embryonic cardiomyocyte cell line H9C2 and primary cultured mouse neonatal cardiomyocytes (CMNCs) were treated with LPS or phosphate-buffered saline (PBS). A mouse model of LPS-induced sepsis was established using male C57BL/6J mice and their cardiomyocytes were collected. Real-time reverse transcription-PCR (qRT-PCR) assay was used to detect the expression levels of Sp1 and ZFAS1 in cardiomyocytes. Western blotting analysis was used to assess the protein expression levels of Sp1, apoptosis-associated proteins and Notch signaling pathway related proteins. Luciferase assay was used to detect the interaction between Sp1 and ZFAS1. Cell transfection was used to generate H9C2 cells with overexpressed or knocked down of Sp1 or ZFAS1. MTT assay and flow cytometry analysis were used to test the cell proliferation and cell apoptosis ratio. RESULTS: Our data revealed that the expressions of ZFAS1 and Sp1 were significantly reduced in LPS-treated H9C2 cells and primary CMNCs. The downregulation of ZFAS1 and Sp1 were also found in cardiomyocytes obtained from LPS-challenged mice. LPS induced H9C2 cell apoptosis and depressed cell proliferation was ameliorated by ZFAS1 overexpression and aggravated by ZFAS1 knockdown. Mechanistically, Luciferase assay indicated that Sp1 could bind to ZFAS1, and positively regulated ZFAS1 expression. Moreover, Notch signaling pathway participates in H9C2 cell apoptosis mediated by Sp1. CONCLUSION: The present study demonstrates that Sp1 regulates LPS-induced cardiomyocyte apoptosis via ZFAS1/Notch signaling pathway, which may serve as therapeutic targets for sepsis-induced myocardial injury.
Subject(s)
Myocardium/metabolism , Myocytes, Cardiac/metabolism , RNA, Long Noncoding/metabolism , Receptors, Notch/metabolism , Sepsis/metabolism , Sp1 Transcription Factor/metabolism , Animals , Apoptosis/physiology , Cell Line , Cell Proliferation/physiology , Down-Regulation/physiology , Male , Mice , Mice, Inbred C57BL , Signal Transduction/physiologyABSTRACT
Background Asthma is a chronic inflammatory heterogeneous respiratory disease. Previous studies showed that the lncRNA NEAT1 (nuclear paraspeckle assembly transcript 1) might play an important role in the pathogenesis of asthma, but its potential mechanism in airway smooth muscle cell (ASMC) inflammation remains largely unknown and needs further investigation.Methods We performed cellular immunofluorescence to identify the features of ASMCs and detected the expression levels of lncRNA NEAT1, miR-139, TNF-α, IL-6, IL-8 and IL-1ß by quantitative real-time PCR (Q-PCR) and ELISA. Western blotting (WB) was used to measure the protein expression of the related genes, and bioinformatics as well as dual luciferase assays were used to validate the interaction between lncRNA NEAT1 and miR-139 and the interaction between miR-139 and the 3'-UTR of JAK3.Results The expression of lncRNA NEAT1 was increased in the ASMCs of asthma patients, but miR-139 was decreased. Overexpression of lncRNA NEAT1 promoted the expression of the inflammatory cytokines such as TNF-α, IL-6, IL-8 and IL-1ß in ASMCs. LncRNA NEAT1 was able to target miR-139 to activate the JAK3/STAT5 signaling pathway and induced the expression of these inflammatory cytokines in ASMCs. Overexpression of miR-139 or suppression of the JAK3/STAT5 signaling pathway reversed the inflammatory effect of lncRNA NEAT1.Conclusion LncRNA NEAT1 played a pivotal role in ASMC inflammation and exerted its function through the miR-139/JAK3/STAT5 signaling network.
Subject(s)
MicroRNAs , Myocytes, Smooth Muscle/pathology , RNA, Long Noncoding , Humans , Inflammation/genetics , Janus Kinase 3 , MicroRNAs/genetics , RNA, Long Noncoding/genetics , STAT5 Transcription FactorABSTRACT
A critical pathogenic factor in the development of lethal liver failure is cell death induced by the accumulation of lipid reactive oxygen species. In this study, we discovered and illuminated a new mechanism that led to alcoholic liver disease via ferroptosis, an iron-dependent regulated cell death. Study in vitro showed that both necroptosis inhibitor and ferroptosis inhibitors performed significantly protective effect on alcohol-induced cell death, while apoptosis inhibitor and autophagy inhibitor had no such effect. Our data also indicated that alcohol caused the accumulation of lipid peroxides and the mRNA expression of prostaglandin-endoperoxide synthase 2, reduced the protein expression of the specific light-chain subunit of the cystine/glutamate antiporter and glutathione peroxidase 4. Importantly, ferrostatin-1 significantly ameliorated liver injury that was induced by overdosed alcohol both in vitro and in vivo. These findings highlight that targeting ferroptosis serves as a hepatoprotective strategy for alcoholic liver disease treatment.
Subject(s)
Cyclohexylamines/pharmacology , Ethanol/toxicity , Ferroptosis/drug effects , Iron/metabolism , Liver Diseases, Alcoholic/genetics , Liver/drug effects , Phenylenediamines/pharmacology , Adenine/analogs & derivatives , Adenine/pharmacology , Amino Acid Chloromethyl Ketones/pharmacology , Amino Acid Transport System y+/genetics , Amino Acid Transport System y+/metabolism , Animals , Autophagy/drug effects , Autophagy/genetics , Cell Line , Cyclooxygenase 2/genetics , Cyclooxygenase 2/metabolism , Disease Models, Animal , Female , Ferroptosis/genetics , Gene Expression Regulation , Hepatocytes/drug effects , Hepatocytes/metabolism , Hepatocytes/pathology , Humans , Imidazoles/pharmacology , Indoles/pharmacology , Lipid Peroxidation/drug effects , Liver/metabolism , Liver/pathology , Liver Diseases, Alcoholic/etiology , Liver Diseases, Alcoholic/pathology , Liver Diseases, Alcoholic/prevention & control , Mice , Mice, Inbred C57BL , Phospholipid Hydroperoxide Glutathione Peroxidase/genetics , Phospholipid Hydroperoxide Glutathione Peroxidase/metabolism , Signal Transduction , Vitamin E/pharmacologyABSTRACT
BACKGROUND: Few large-scale studies have demonstrated the efficacy of tobramycin nebulization in bronchiectasis. We evaluated the efficacy and safety of nebulized tobramycin inhalation solution (TIS) in adults with bronchiectasis with Pseudomonas aeruginosa infection. RESEARCH QUESTION: Can TIS effectively reduce sputum P aeruginosa density and improve the bronchiectasis-specific quality of life in patients with bronchiectasis with P aeruginosa infection? STUDY DESIGN AND METHODS: This was a phase 3, 16-week, multicenter, randomized, double-blind, placebo-controlled trial. Eligible adults with bronchiectasis were recruited from October 2018 to July 2021. On the basis of usual care, patients nebulized TIS (300 mg/5 mL twice daily) or normal saline (5 mL twice daily) via vibrating-mesh nebulizer. Treatment consisted of two cycles, each consisting of 28 days on-treatment and 28 days off-treatment. The coprimary end points included changes from baseline in P aeruginosa density and Quality-of-Life Bronchiectasis Respiratory Symptoms score on day 29. RESULTS: The modified intention-to-treat population consisted of 167 patients in the tobramycin group and 172 patients in the placebo group. Compared with placebo, TIS resulted in a significantly greater reduction in P aeruginosa density (adjusted mean difference, 1.74 log10 colony-forming units/g; 95% CI, 1.12-2.35; P < .001) and greater improvement in Quality-of-Life Bronchiectasis Respiratory Symptoms score (adjusted mean difference, 7.91; 95% CI, 5.72-10.11; P < .001) on day 29. Similar findings were observed on day 85. TIS resulted in a significant reduction in 24-h sputum volume and sputum purulence score on days 29, 57, and 85. More patients became culture negative for P aeruginosa in the tobramycin group than in the placebo group on day 29 (29.3% vs 10.6%). The incidence of adverse events and serious adverse events were comparable between the two groups. INTERPRETATION: TIS is an effective treatment option and has an acceptable safety profile in patients with bronchiectasis with P aeruginosa infection. TRIAL REGISTRATION: ClinicalTrials.gov; No. NCT03715322; URL: www. CLINICALTRIALS: gov.
Subject(s)
Bronchiectasis , Pseudomonas Infections , Humans , Adult , Tobramycin , Pseudomonas Infections/complications , Pseudomonas Infections/drug therapy , Anti-Bacterial Agents/therapeutic use , Quality of Life , Administration, Inhalation , Bronchiectasis/complications , Bronchiectasis/drug therapy , Double-Blind Method , Pseudomonas aeruginosaABSTRACT
Long non-coding RNA ZFAS1 is down-regulated in sepsis. However, whether ZFAS1 participates in sepsis-induced cardiomyopathy (SIC) remains largely unknown. LPS injection to rats was used to establish an in vivo sepsis model, while LPS stimulation with H9C2 cell was used to mimic an in vitro sepsis-induced myocardial injury model. Western blots and quantitative RT-PCR were performed to evaluate protein and mRNA levels, respectively. ELISA was conducted to determine cytokine levels in supernatant. Flow cytometry was used to test apoptosis. Dual-luciferase assay was performed to validate binding between ZFAS1 and miR-34b-5p, miR-34b-5p and SIRT1. Our data revealed that ZFAS1 and SIRT1 were down-regulated, while miR-34b-5p was up-regulated in LPS-induced H9C2 cells. Inhibition of miR-34b-5p or overexpression of ZFAS1 alleviated inflammatory response and cell apoptosis in LPS-stimulated H9C2 cells. A mechanism study revealed that ZFAS1 sponged miR-34b-5p and thus elevated expression of SIRT1, which was prohibited by miR-34b-5p. ZFAS1 alleviated inflammatory response and cell apoptosis in LPS-stimulated H9C2 cells via the miR-34b-5p/SIRT1 axis, providing novel potential therapeutic targets for SIC.
Subject(s)
MicroRNAs/genetics , Myocardium/pathology , Myocytes, Cardiac/physiology , RNA, Long Noncoding/genetics , Sepsis/genetics , Sirtuin 1/metabolism , Animals , Cell Line , Disease Models, Animal , Gene Expression Regulation , Humans , Lipopolysaccharides/immunology , Male , Myocardium/metabolism , Rats , Rats, Sprague-Dawley , Sirtuin 1/geneticsABSTRACT
Three new ester glycosides, named as Caesateroside A (1), Caesateroside B (2) and Caesateroside C (3) were obtained from the seeds of Caesalpinia sappan. The new structures of compounds 1-3 were elucidated by analyzing their 1 D NMR, 2 D NMR and HR-ESI-MS spectra. Compounds 1-3 showed weak-moderate cytotoxicity against Hela and HepG-2 human cancer cell lines.
Subject(s)
Caesalpinia , Diterpenes , Esters , Glycosides/pharmacology , Humans , Molecular Structure , SeedsABSTRACT
Bronchial asthma poses a serious threat to human health. Previous studies have documented the role of long noncoding RNAs (lncRNAs) in asthma. However, the molecular mechanism underlying bronchial asthma remains unclear. The aim of the present study was to evaluate the role of the lncRNA Opainteracting protein 5 antisense RNA1 (OIP5AS1) in the house dust miteinduced inflammatory response in human bronchial epithelial cells. BEAS2B cells were treated with Dermatophagoides pteronyssinus peptidase 1 (Der p1) to establish an in vitro model of asthma. OIP5AS1 expression levels increased in BEAS2B cells following Der p1 treatment, while microRNA (miR)1433p was downregulated. Additionally, the levels of the proinflammatory factors tumor necrosis factorα, interleukin (IL)6 and IL8 were measured, and apoptosis was evaluated following OIP5 silencing. OIP5AS1 knockdown reduced the inflammatory response and apoptosis in BEAS2B cells. Furthermore, using dual luciferase reporter assays and cotransfection experiments, it was demonstrated that the function of OIP5AS1 was mediated by miR1433p. miR1433p overexpression attenuated the Der p1induced inflammatory response and apoptosis of BEAS2B cells by targeting high mobility group box 1 (HMGB1). In summary, OIP5AS1 exacerbated Der p1induced inflammation and apoptosis in BEAS2B cells by targeting miR1433p via HMGB1.